Azoles display promising anticonvulsant effects through possible PPAR-α activation

• Published in: Neuroscience letters 2024-04, Vol.828, p.137750-137750, Article 137750
• Main Authors: Sari, Suat, Yurtoğlu, Sibel, Zengin, Merve, Marcinkowska, Monika, Siwek, Agata, Saraç, Selma
• Format: Article
• Language: English
• Subjects: 6 Hz; Animals; Anticonvulsants - pharmacology; Azoles; Blood–brain barrier molecular docking; Epilepsy; Esters; gamma-Aminobutyric Acid; MES; Mice; Molecular Docking Simulation; PPAR alpha; PPAR-α; Seizures - drug therapy; Structure-Activity Relationship
• ISSN: 0304-3940; 1872-7972
• DOI: 10.1016/j.neulet.2024.137750

[Display omitted] Azoles such as nafimidone, denzimol and loreclezole are known for their clinical efficacy against epilepsy, and loreclezole acts by potentiating γ-aminobutyric acid (GABA)-ergic currents. In the current study, we report a series of azole derivatives in alcohol ester and oxime ester structure showing promising anticonvulsant effects in 6 Hz and maximal electro shock (MES) models with minimal toxicity. The most promising of the series, 5f, was active in both 6 Hz and MES tests with a median effective dose (ED50) of 118.92 mg/kg in 6 Hz test and a median toxic dose (TD50) twice as high in mice. The compounds were predicted druglike and blood–brain barrier (BBB) penetrant in silico. Contrary to what was expected, the compounds showed no in vitro affinity to GABAA receptors (GABAARs) in radioligand binding assays; however, they were found structurally similar to peroxisome proliferator-activated receptors alpha (PPAR-α) agonists and predicted to show high affinity and agonist-like binding to PPAR-α in molecular docking studies. As a result, 5f emerged as a safe azole anticonvulsant with a wide therapeutic window and possible action through PPAR-α activation.